Hansa Biopharma AB (publ) (HNSA.ST)
SEK 26.78
(13.09%)
SEK 26.78
(13.09%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.18 Billion SEK | 9.35% |
| 2022 | 1.08 Billion SEK | 324.9% |
| 2021 | 255.23 Million SEK | 32.68% |
| 2020 | 192.37 Million SEK | 89.68% |
| 2019 | 101.42 Million SEK | 19.4% |
| 2018 | 84.94 Million SEK | 70.73% |
| 2017 | 49.75 Million SEK | 84.42% |
| 2016 | 26.97 Million SEK | 114.77% |
| 2015 | 12.56 Million SEK | 178.72% |
| 2014 | 4.5 Million SEK | -11.57% |
| 2013 | 5.09 Million SEK | 99.38% |
| 2012 | 2.55 Million SEK | -58.7% |
| 2011 | 6.18 Million SEK | 9.82% |
| 2010 | 5.63 Million SEK | -57.39% |
| 2009 | 13.22 Million SEK | 220.05% |
| 2008 | 4.13 Million SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.2 Billion SEK | 1.59% |
| 2024 Q2 | 1.24 Billion SEK | 3.6% |
| 2024 Q3 | 1.26 Billion SEK | 1.0% |
| 2023 FY | 1.18 Billion SEK | 9.35% |
| 2023 Q4 | 1.18 Billion SEK | -3.84% |
| 2023 Q2 | 1.18 Billion SEK | 8.78% |
| 2023 Q1 | 1.08 Billion SEK | 0.05% |
| 2023 Q3 | 1.23 Billion SEK | 4.48% |
| 2022 FY | 1.08 Billion SEK | 324.9% |
| 2022 Q3 | 1.03 Billion SEK | 242.05% |
| 2022 Q1 | 253.51 Million SEK | -0.67% |
| 2022 Q2 | 302.93 Million SEK | 19.49% |
| 2022 Q4 | 1.08 Billion SEK | 4.66% |
| 2021 Q1 | 160.9 Million SEK | -16.36% |
| 2021 FY | 255.23 Million SEK | 32.68% |
| 2021 Q3 | 192.7 Million SEK | 3.02% |
| 2021 Q4 | 255.23 Million SEK | 32.45% |
| 2021 Q2 | 187.05 Million SEK | 16.25% |
| 2020 Q4 | 192.37 Million SEK | 2.18% |
| 2020 Q3 | 188.26 Million SEK | 130.46% |
| 2020 FY | 192.37 Million SEK | 89.68% |
| 2020 Q1 | 65.54 Million SEK | -35.38% |
| 2020 Q2 | 81.69 Million SEK | 24.64% |
| 2019 Q2 | 62.41 Million SEK | -0.87% |
| 2019 Q4 | 101.42 Million SEK | 50.83% |
| 2019 Q3 | 67.24 Million SEK | 7.74% |
| 2019 Q1 | 62.95 Million SEK | -25.88% |
| 2019 FY | 101.42 Million SEK | 19.4% |
| 2018 Q1 | 55.62 Million SEK | 11.81% |
| 2018 Q2 | 60.92 Million SEK | 9.52% |
| 2018 Q4 | 84.94 Million SEK | 33.38% |
| 2018 Q3 | 63.68 Million SEK | 4.53% |
| 2018 FY | 84.94 Million SEK | 70.73% |
| 2017 Q4 | 49.75 Million SEK | 84.09% |
| 2017 Q1 | 26.08 Million SEK | -3.31% |
| 2017 Q3 | 27.02 Million SEK | -10.57% |
| 2017 Q2 | 30.22 Million SEK | 15.86% |
| 2017 FY | 49.75 Million SEK | 84.42% |
| 2016 Q3 | 19.96 Million SEK | -5.0% |
| 2016 Q4 | 26.97 Million SEK | 35.11% |
| 2016 Q2 | 21.01 Million SEK | 60.66% |
| 2016 FY | 26.97 Million SEK | 114.77% |
| 2016 Q1 | 13.08 Million SEK | 4.15% |
| 2015 Q4 | 12.56 Million SEK | 27.38% |
| 2015 Q3 | 9.86 Million SEK | -21.75% |
| 2015 Q2 | 12.6 Million SEK | -16.2% |
| 2015 Q1 | 15.04 Million SEK | 233.73% |
| 2015 FY | 12.56 Million SEK | 178.72% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | 4.86 Million SEK | 0.0% |
| 2014 Q4 | 4.5 Million SEK | 0.0% |
| 2014 FY | 4.5 Million SEK | -11.57% |
| 2013 Q1 | 2.91 Million SEK | 13.88% |
| 2013 FY | 5.09 Million SEK | 99.38% |
| 2013 Q4 | 5.09 Million SEK | -3.2% |
| 2013 Q3 | 5.26 Million SEK | 80.87% |
| 2013 Q2 | 2.91 Million SEK | 0.0% |
| 2012 Q2 | 2.25 Million SEK | 0.0% |
| 2012 FY | 2.55 Million SEK | -58.7% |
| 2012 Q4 | 2.55 Million SEK | 0.0% |
| 2011 FY | 6.18 Million SEK | 9.82% |
| 2011 Q4 | 6.18 Million SEK | 0.0% |
| 2011 Q2 | 4.44 Million SEK | 0.0% |
| 2010 Q2 | 3.37 Million SEK | 0.0% |
| 2010 FY | 5.63 Million SEK | -57.39% |
| 2010 Q4 | 5.63 Million SEK | 0.0% |
| 2009 Q2 | 4.71 Million SEK | 0.0% |
| 2009 Q4 | 13.22 Million SEK | 0.0% |
| 2009 FY | 13.22 Million SEK | 220.05% |
| 2008 Q4 | 4.13 Million SEK | 0.0% |
| 2008 FY | 4.13 Million SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Asarina Pharma AB (publ) | 4.42 Million SEK | -26694.329% |
| BioArctic AB (publ) | 139.5 Million SEK | -750.101% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -50172.022% |
| CombiGene AB (publ) | 4.15 Million SEK | -28435.065% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | -1567.534% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -8511.34% |
| OncoZenge AB (publ) | 1.69 Million SEK | -69700.883% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | -1012.545% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 24.259% |
| Mendus AB (publ) | 51.22 Million SEK | -2215.114% |
| LIDDS AB (publ) | 3.75 Million SEK | -31473.935% |
| Lipum AB (publ) | 7.53 Million SEK | -15632.515% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | -856.547% |
| Simris Alg AB (publ) | 148.93 Million SEK | -696.249% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -10063.841% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -22728.297% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | -145.953% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | -1550.546% |
| Ziccum AB (publ) | 6.38 Million SEK | -18464.762% |
| AcouSort AB (publ) | 10.37 Million SEK | -11327.221% |
| Active Biotech AB (publ) | 13.4 Million SEK | -8750.127% |
| Alzinova AB (publ) | 9.33 Million SEK | -12609.431% |
| Amniotics AB (publ) | 10.54 Million SEK | -11144.117% |
| Camurus AB (publ) | 414.81 Million SEK | -185.888% |
| Cantargia AB (publ) | 54.97 Million SEK | -2057.389% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -30799.349% |
| Genovis AB (publ.) | 98.04 Million SEK | -1109.539% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -6312.442% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -6088.254% |
| Intervacc AB (publ) | 21.68 Million SEK | -5370.097% |
| Kancera AB (publ) | 17.97 Million SEK | -6496.49% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -10150.817% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -22891.799% |
| NextCell Pharma AB | 13.68 Million SEK | -8563.25% |
| Saniona AB (publ) | 86.08 Million SEK | -1277.644% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | -2802.462% |
| Xintela AB (publ) | 14.01 Million SEK | -8361.77% |
| Sprint Bioscience AB (publ) | 34.6 Million SEK | -3327.209% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -4340.306% |
| Corline Biomedical AB | 6.78 Million SEK | -17368.213% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | -1832.815% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -7258.175% |
| Aptahem AB (publ) | 8.99 Million SEK | -13080.038% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | -2468.032% |
| Fluicell AB (publ) | 8.91 Million SEK | -13202.49% |
| Biovica International AB (publ) | 34.76 Million SEK | -3311.042% |
| Abliva AB (publ) | 16.78 Million SEK | -6967.022% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | -452.617% |
| 2cureX AB (publ) | 2.93 Million SEK | -40306.031% |
| I-Tech AB | 16.2 Million SEK | -7218.217% |
| Cyxone AB (publ) | 4.69 Million SEK | -25164.529% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -8797.937% |
| Biosergen AB | 5.08 Million SEK | -23221.868% |
| Nanologica AB (publ) | 79.32 Million SEK | -1394.973% |
| SynAct Pharma AB | 51.83 Million SEK | -2187.913% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -14819.072% |
| BioInvent International AB (publ) | 90.45 Million SEK | -1211.086% |
| Oncopeptides AB (publ) | 181.59 Million SEK | -553.045% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -66004.627% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -9205.689% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -16234.945% |